Summary
The oncoprotein encoded by mutantras genes is initially synthesized as a cytoplasmic precursor which requires posttranslational processing to attain biological activity; farnesylation of the cysteine residue present in the CaaX motif located at the carboxy-terminus of all Ras proteins is the critical modification. Once farnesylated and further modified, the mature Ras protein is inserted into the cell's plasma membrane where it participates in the signal transduction pathways that control cell growth and differentiation. The farnesylation reaction that modifies Ras and other cellular proteins having an appropriate CaaX motif is catalyzed by a housekeeping enzyme termed farnesyl-protein transferase (FPTase). Inhibitors of this enzyme have been prepared by several laboratories in an effort to identify compounds that would block Ras-induced cell transformation and thereby function as Ras-specific anticancer agents. A variety of natural products and synthetic organic compounds were found to block farnesylation of Ras proteinsin vitro. Some of these compounds exhibit antiproliferative activity in cell culture, block the morphological alterations associated with Ras-transformation, and can block the growth of Ras-transformed cell lines in tumor colony-forming assays. By contrast, these compounds do not affect the growth or morphology of cells transformed by the Raf or Mos oncoproteins, which do not require farnesylation to achieve biological activity. The efficacy and lack of toxicity observed with FPTase inhibitors in an animal tumor model suggest that specific FPTase inhibitors may be useful for the treatment of some types of cancer.
Similar content being viewed by others
References
Lowy DR, Willumsen BM: Function and regulation of Ras. Annu Rev Biochem 62:851–891, 1993
McCormick F: Activators and effectors ofras p21 proteins. Curr Opin Genetics Devel 4:71–76, 1994
Prendergast GC, Gibbs JB: Pathways of Ras function. Adv Cancer Res 62:19–64, 1993
Clarke S: Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 61:355–386, 1992
Cox AD, Der CJ: Protein prenylation: more than just glue? Curr Opin Cell Biol 4:1008–1016, 1992
Gibbs JB: Ras C-terminal processing enzymes — new drug targets? Cell 65:1–4, 1991
Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesbroeck B, Gout I, Fry MJ, Waterfield MD, Downward J: Phosphatidylinositol 3-OH kinase as a direct target of Ras. Nature 370:527–532, 1994
Bollag G, McCormick F: Regulators and effectors ofras proteins. Annu Rev Cell Biol 7:601–632, 1991
Polakis P, McCormick F: Structural requirements for the interaction of p21ras with GAP, exchange factors, and its biological effector target. J Biol Chem 268: 9157–9160, 1993
Wittinghofer A, Pai EF: The structure of Ras protein: a model for a universal molecular switch. Trends Biochem Sci 16:382–387, 1991
Gibbs JB: Pharmacological probes of Ras function. Semin Cancer Biol 3:383–390, 1992
Warne PH, Rodriguez-Viciana P, Downward J: Direct interaction of Ras and the amino-terminal domain of Raf-1 in vitro. Nature 364:352–355, 1993
Pawson T, Gish GD: SH2 and SH3 domains: from structure to function. Cell 71:359–362, 1992
Chen W-J, Moomaw JF, Overton L, Kost TA, Casey PJ: High level expression of mammalian protein farnesyltransferase in a baculovirus system: the purified protein contains zinc. J Biol Chem 268:9675–9680, 1993
Omer CA, Kral AM, Diehl RE, Prendergast GC, Powers S, Allen CM, Gibbs JB, Kohl NE: Characterization of recombinant human farnesyl-protein transferase: cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenylprotein transferases. Biochemistry 32:5167–5176, 1993
Reiss Y, Seabra MC, Armstrong SA, Slaughter CA, Goldstein JL, Brown MS: Nonidentical subunits of p21H-ras farnesyltransferase: peptide binding and farnesyl diphosphate carrier functions. J Biol Chem 266:10672–10677, 1991
Pompliano DL, Rands E, Schaber MD, Mosser SD, Anthony NJ, Gibbs JB: Steady-state kinetic mechanism of Ras farnesyl-protein transferase. Biochemistry 31:3800–3807, 1992
Patel DV, Gordon EM, Schmidt RJ, Weller HN, Young MG, Zahler R, Barbacid M, Carboni JM, Gullo-Brown JL, Hunihan L, Ricca C, Robinson S, Seizinger BR, Tuomari AV, Manne V: Phosphinyl acid-based bisubstrate analog inhibitors of Ras farnesyl-protein transferase. J Med Chem 38:435–442, 1995
Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77: 175–178, 1994
Graham SL, deSolms SJ, Giuliani EA, Kohl NE, Mosser SD, Oliff AI, Pompliano DL, Rands E, Breslin MJ, Deana AA, Garsky VM, Scholz TH, Gibbs JB, Smith RL: Pseudopeptide inhibitors of Ras farnesyl-protein transferase. J Med Chem 37:725–732, 1994
Tamanoi F: Inhibitors of Ras farnesyltransferase. Trends Biochem Sci 18:349–353, 1993
Gibbs JB, Pompliano DL, Mosser SD, Rands E, Lingham RB, Singh SB, Scolnick EM, Kohl NE, Oliff A: Selective inhibition of farnesyl-protein transferase blocks Ras processingin vivo. J Biol Chem 268: 7617–7620, 1993
Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, Tamanoi F: Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90:2281–2285, 1993
Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of rasdependent transformation by a farnesyltransferase inhibitor. Science 260:1934–1937, 1993
Kohl NE, Wilson FR, Mosser SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91:9141–9145, 1994
James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC Jr: Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260: 1937–1942, 1993
Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE: Farnesyl-transferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14: 4193–4202, 1994
James GL, Goldstein JL, Pathak RK, Anderson RGW, Brown MS: PXF, a prenylated protein of peroxisomes. J Biol Chem 269:14182–14190, 1994
Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85–88, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gibbs, J.B., Kohl, N.E., Koblan, K.S. et al. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res Tr 38, 75–83 (1996). https://doi.org/10.1007/BF01803786
Issue Date:
DOI: https://doi.org/10.1007/BF01803786